

1-2 1-5 2-3 3-4 4-5

exact/norm bonds :

1-2 1-5 1-7 2-3 3-4 4-5 5-6 8-9 10-11 11-12

exact bonds :

2-10 7-8

G1:O,S,N

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:CLASS 9:CLASS


10:CLASS 11:CLASS 12:Atom

L17 STRUCTURE UPLOADED

=> d

L17 HAS NO ANSWERS

L17 STR



G1 O,S,N

Structure attributes must be viewed using STN Express query preparation.

=> s l17

SAMPLE SEARCH INITIATED 13:16:46 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 88 TO ITERATE

100.0% PROCESSED 88 ITERATIONS

9 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 1198 TO 2322

PROJECTED ANSWERS: 9 TO 360

L18 9 SEA SSS SAM L17

=> s 117 full
FULL SEARCH INITIATED 13:16:49 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 1835 TO ITERATE

100.0% PROCESSED 1835 ITERATIONS 170 ANSWERS
SEARCH TIME: 00.00.01

L19 170 SEA SSS FUL L17

=> fil caplus
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
166.94	858.07

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
0.00	-3.00

CA SUBSCRIBER PRICE

FILE 'CAPLUS' ENTERED AT 13:16:52 ON 11 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 11 Dec 2006 VOL 145 ISS 25
FILE LAST UPDATED: 10 Dec 2006 (20061210/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 119

L20 7 L19


=> d ibib abs hitstr tot

OTHER SOURCE(S): MARPAT 144:419688
AB Disclosed is a medicinal composition for inhalation containing a continuous-release
type prodrg of an EP2 agonist topically exhibits a prolonged
bronchodilating and antiinflammatory effects. Namely, the medicinal
composition for inhalation containing a continuous-release type prodrg
of an
agonist is useful as a safe preventive and/or a remedy for respiratory
diseases (for example, asthma, pulmonary injury, pulmonary fibrosis,
pulmonary emphysema, bronchitis, chronic obstructive pulmonary disease,
adult respiratory distress syndrome, cystic fibrosis, pulmonary
hypertension or the like) without causing any systemic effect such as
lowering blood pressure. Thus, a safe and useful remedy for respiratory
diseases is provided. For example, the long-lasting bronchodilatory
effect of undecyl 2'-[2-[(2R)-2'-[(3,5-dichlorophenoxy)methyl]-5-
oxopyrrolidin-1-yl]ethyl]sulfonyl-1,3-thiazole-4-carboxylate was
examined
in guinea pigs.
IT 883978-33-4P 883978-34-5P 883978-35-6P
883978-36-7P 883978-37-8P 883978-38-9P
883978-39-0P 883978-40-3P 883978-54-9P
883978-55-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(medicinal composition containing EP2 agonists for inhalation)
RN 883978-33-4 CAPLUS
CR 4-thiazolecarboxylic acid, 2-[[2-[(2R)-2'-[(5-heptyl-2-

CC(C)C1=CC=C(C=C1)COC[C@H]2CC[C@@H](C2)N(CCCS3C=NC(C=C3)C(=O)O)C4=CC=C(C=C4)C=CCC1(C)C(=O)N(C1CCSC2=CN(C=C2)C(=O)O)C[C@H](C1=CC=C(C=C1)OC)OCCCCCCC(COC(=O)N1CCCC1=O)Cc2ccc(Cl)cc2SCCn3cnc(C(=O)O)s3CC1=CC=C(OC[C@H]2CC[C@@H](N2CSC3=CN=C(S3)C(=O)O)C1=CC=C(C)C)CCCC1=CC=C(C=C1C(=O)OCC2=NC=CC=C2S2)OC[C@H]3CC(=O)N3CCc1cc(OC[C@H](C)N(CCCCSc2nc(C(=O)O)csc2)C(=O)c3ccc(C)cc3)ccc1CCCCCCCCCCCCCCCCCOC(=O)c1cc(s1)SCCN2C(=O)CC[C@H]2COc3ccc(Cl)cc3


Absolute stereochemistry.

L20 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 883978-54-9 CAPLUS
CN 4-Thiazolecarboxylic acid, 2-[[2-[(2R)-2-[(3,5-dichlorophenoxy)methyl]-5-oxo-1-pyrrolidinyl]ethyl]thio]-, 2-[(1-oxodecyl)oxy]ethyl ester (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 883978-55-0 CAPLUS
CN 4-Thiazolecarboxylic acid, 2-[[2-[(2R)-2-[(3,5-dichlorophenoxy)methyl]-5-oxo-1-pyrrolidinyl]ethyl]thio]-, 10-hydroxydecyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 597571-74-9 597572-55-9 597572-63-9
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

L20 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



IT 597572-16-2
RL: PAC (Pharmacological activity); RCT (Reactant); THU (Therapeutic use);
BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
(preparation of medicinal composition containing EP2 agonists for inhalation)
RN 597572-16-2 CAPLUS
CN 4-Thiazolecarboxylic acid, 2-[[2-[(2R)-2-[(3,5-dichlorophenoxy)methyl]-5-oxo-1-pyrrolidinyl]ethyl]thio]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 883978-32-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of medicinal composition containing EP2 agonists for inhalation)
RN 883978-32-3 CAPLUS
CN 4-Thiazolecarboxylic acid, 2-[[2-[(2R)-2-[(5-heptyl-2-methylphenoxy)methyl]-5-oxo-1-pyrrolidinyl]ethyl]thio]-, butyl ester (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

L20 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
(Biological study); USES (Uses)
(medicinal compn. contg. EP2 agonists for inhalation).


RN 597571-74-9 CAPLUS
CN 4-Thiazolecarboxylic acid, 2-[[2-[(2R)-2-[(3,5-dichlorophenoxy)methyl]-5-oxo-1-pyrrolidinyl]ethyl]thio]-, butyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 597572-55-9 CAPLUS
CN 4-Thiazolecarboxylic acid, 2-[[2-[(2R)-2-[(2-chloro-3-(trifluoromethyl)phenoxy)methyl]-5-oxo-1-pyrrolidinyl]ethyl]thio]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 597572-63-9 CAPLUS
CN 4-Thiazolecarboxylic acid, 2-[[2-[(2R)-2-oxo-5-[[3-(trifluoromethoxy)phenoxy]methyl]-1-pyrrolidinyl]ethyl]thio]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L20 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L20 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 2005:588954 CAPLUS
 DOCUMENT NUMBER: 143:115526
 TITLE: Preparation of thiazolecarboxylate derivatives as EP2 agonist for treatment of glaucoma
 INVENTOR(S): Yamane, Shinsaku; Narita, Masami; Tani, Kousuke; Kobayashi, Kaoru
 PATENT ASSIGNEE(S): Ono Pharmaceutical Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 63 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005061492	A1	20050707	WO 2004-JP19660	20041221

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MG, MK, MN, MW, MX, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SV, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: JIP 2003-425400 A 20031222


OTHER SOURCE(S): MARPAT 143:115526
 GI



AB Title compds. represented by the formula I [wherein A = (un)substituted hydrocarbon; R1 = (halo)hydrocarbon; and their salts, solvates, prodrugs or cyclodextrin clathrates thereof] were prepared as EP2 agonist. For example, reaction of II (R = OH) with iso-Pr iodide gave II (R = OPr-i). Recrystd. II was studied by X-ray diffraction spectrum, IR spectrum and DSC measurement, and showed EP2 agonist activity. Thus, I and their pharmaceutical compns. are useful as EP2 agonist for the treatment of eye diseases such as glaucoma.


IT 857255-43-7P
 RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic)

L20 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)
 Absolute stereochemistry.




RN 857255-48-2 CAPLUS
 CN 4-Thiazolecarboxylic acid, 2-[[2-[(2R)-2-oxo-5-[(2,3,4-trichlorophenoxy)methyl]-1-pyrrolidinyl]ethyl]thio]-, 1-methylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 857255-49-3 CAPLUS
 CN 4-Thiazolecarboxylic acid, 2-[[2-[(2R)-2-[(4-chloro-3,5-dimethylphenoxy)methyl]-5-oxo-1-pyrrolidinyl]ethyl]thio]-, 1-methylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 857255-50-6 CAPLUS
 CN 4-Thiazolecarboxylic acid, 2-[[2-[(5R)-2-oxo-5-[(2,3,5-

L20 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)
 preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of thiazole-4-carboxylate derivs. as EP2 agonist for treatment of glaucoma)
 RN 857255-43-7 CAPLUS
 CN 4-Thiazolecarboxylic acid, 2-[[2-[(2R)-2-[(3,5-dichlorophenoxy)methyl]-5-oxo-1-pyrrolidinyl]ethyl]thio]-, 1-methylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 857255-44-8P 857255-47-1P 857255-48-2P
 857255-49-3P 857255-50-6P 857255-51-7P
 857255-52-8P 857255-53-9P 857255-54-0P
 857255-55-1P 857255-56-2P 857255-56-3P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of thiazole-4-carboxylate derivs. as EP2 agonist for treatment of glaucoma)

RN 857255-44-8 CAPLUS
 CN 4-Thiazolecarboxylic acid, 2-[[2-[(2R)-2-[(3,5-dichlorophenoxy)methyl]-5-oxo-1-pyrrolidinyl]ethyl]thio]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 857255-47-1 CAPLUS
 CN 4-Thiazolecarboxylic acid, 2-[[2-[(2R)-2-[(2-chloro-3-(trifluoromethyl)phenoxy)methyl]-5-oxo-1-pyrrolidinyl]ethyl]thio]-, 1-methylethyl ester (9CI) (CA INDEX NAME)


L20 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)
 trichlorophenoxy)methyl]-1-pyrrolidinyl]ethyl]thio]-, 1-methylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 857255-51-7 CAPLUS
 CN 4-Thiazolecarboxylic acid, 2-[[2-[(2R)-2-[(4-chloro-2,6-dimethylphenoxy)methyl]-5-oxo-1-pyrrolidinyl]ethyl]thio]-, 1-methylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 857255-52-8 CAPLUS
 CN 4-Thiazolecarboxylic acid, 2-[[2-[(2R)-2-[(4-chloro-3-(trifluoromethyl)phenoxy)methyl]-5-oxo-1-pyrrolidinyl]ethyl]thio]-, 1-methylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 857255-53-9 CAPLUS
 CN 4-Thiazolecarboxylic acid, 2-[[2-[(2R)-2-[(4-chloro-3-ethylphenoxy)methyl]-5-oxo-1-pyrrolidinyl]ethyl]thio]-, 1-methylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 857255-54-0 CAPLUS
 CN 4-Thiazolecarboxylic acid, 2-[[2-[(2R)-2-[(3,4-dichlorophenoxy)methyl]-5-oxo-1-pyrrolidinyl]ethyl]thio]-, 1-methylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 857255-55-1 CAPLUS
 CN 4-Thiazolecarboxylic acid, 2-[[2-[(5R)-2-oxo-5-[[5,6,7,8-tetrahydro-1-naphthalenyl]oxy]methyl]-1-pyrrolidinyl]ethyl]thio]-, 1-methylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

RL: RCT (Reactant); RACT (Reactant or reagent)
 (prepn. of thiazole-4-carboxylate derivs. as EP2 agonist for treatment of glaucoma)
 RN 597572-16-2 CAPLUS
 CN 4-Thiazolecarboxylic acid, 2-[[2-[(2R)-2-[(3,5-dichlorophenoxy)methyl]-5-oxo-1-pyrrolidinyl]ethyl]thio]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT




RN 857255-56-2 CAPLUS
 CN 4-Thiazolecarboxylic acid, 2-[[2-[(5R)-2-oxo-5-[[3-(trifluoromethoxy)phenoxy]methyl]-1-pyrrolidinyl]ethyl]thio]-, 1-methylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 857255-65-3 CAPLUS
 CN 4-Thiazolecarboxylic acid, 2-[[2-[(2R)-2-[(3,5-dichlorophenoxy)methyl]-5-oxo-1-pyrrolidinyl]ethyl]thio]-, 2,2,2-trifluoroethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 597572-16-2

ACCESSION NUMBER: 2005:523298 CAPLUS
 DOCUMENT NUMBER: 143:53530
 TITLE: Blood flow promoters for cauda equina tissues containing prostaglandin-like compounds
 Ohmoto, Kazuyuki; Kinoshita, Akihiro; Kamanaka, Yoshihisa; Matsuya, Hidekazu
 INVENTOR(S): Ono Pharmaceutical Co., Ltd., Japan
 PATENT ASSIGNEE(S):
 SOURCE: PCT Int. Appl., 132 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005053707	A1	20050616	WO 2004-JP17961	20041202
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LG, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SV, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1707208	A1	20061004	EP 2004-819909	20041202
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS			
PRIORITY APPLN. INFO.:			JP 2003-407675	A 20031205
			WO 2004-JP17961	W 20041202

OTHER SOURCE(S): MARPAT 143:53530
 AB It is intended to provide highly safe and efficacious blood flow promoters for cauda equina tissues. Among prostaglandin-like compounds having a weak hypotensive effect, compounds having an effect of promoting the blood flow in cauda equina tissues (excluding limprost) are useful as highly safe blood flow promoters for cauda equina tissues and, therefore, are efficacious in preventing and/or treating lumbar pain, lower limb pain, lower limb palsy, intermittent claudication, vesicorectal failure, hypogonadism, etc. caused by cauda equina injuries. Thus, 2-[[2-[(4S)-4-[[1E,3R]-3-[[1-(4-fluorobutyl)cyclobutyl]-3-hydroxy-1-propenyl]-2-oxo-1,3-oxazolidin-3-yl]ethyl]sulfanyll]-1,3-thiazole-4-carboxylic acid (I) was prepared. The compound I improved blood flow of cauda equina in rats without significantly affecting blood pressure. Also, a tablet containing I 0.5 mg/tablet was formulated.
 IT
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (blood flow promoters for cauda equina tissues containing prostaglandin-like compounds.)
 RN 853998-92-2 CAPLUS
 CN 4-Thiazolecarboxylic acid, 2-[[2-[(1R,2R,5S)-2-[(3,5-dichlorophenoxy)methyl]-4-oxo-3-azabicyclo[3.1.0]hex-3-yl]ethyl]thio]-

Absolute stereochemistry.



REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR
THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT


L20 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:325685 CAPLUS
DOCUMENT NUMBER: 142:397733
TITLE: Sustained release pharmaceutical compounds to prevent
abuse of controlled substances
INVENTOR(S): Mickle, Travis; Krishnan, Suma; Moncrief, James
Scott;
PATENT ASSIGNEE(S): Lauderback, Christopher; Piccarillo, Thomas
New River Pharmaceuticals Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 42 pp., Cont.-in-part of Appl.
No. PCT/US03/05525.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 20
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005080012	A1	20050414	US 2004-923257	20040823
WO 2003072046	A2	20030904	WO 2003-US5525	20030224
WO 2003072046	A3	20050310		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GW, GQ, ML, MR, NE, SN, TD, TG				
US 2006014697	A1	20060119	US 2005-89056	20050325
PRIORITY APPL. INFO.:				
			US 2002-358368P	P 20020222
			US 2002-362082P	P 20020307
			WO 2003-US5525	A2 20030224
			US 2001-933708	A2 20010822
			US 2002-358381P	P 20020222
			US 2002-366258P	P 20020322
			US 2002-156527	A2 20020529
			US 2003-507012P	P 20030930
			US 2004-567800P	P 20040505
			US 2004-567802P	P 20040505
			US 2004-568011P	P 20040505
			US 2004-923088	A2 20040823
			US 2004-923257	A2 20040823
			US 2004-953110	A2 20040930

L20 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
US 2004-953111 A2 20040930
US 2004-953116 A2 20040930
US 2004-953119 A2 20040930
US 2004-955006 A2 20040930
WO 2004-US32131 A2 20040930

AB The present invention provides methods for altering controlled substances in a manner that decreases their potential for abuse. The novel compds. may be combined in tablets with suitable excipients or formulated in solution for oral delivery. When delivered by the oral route the controlled substance is released in a time-dependent manner (sustained release) by acid hydrolysis and/or enzymic cleavage. When administered by injection the controlled substance is released in a time-dependent manner (sustained release) by way of serum enzymes. Conjugates such as polyserine-naltrexone and hydrocodone and oxycodone peptide conjugates were prepared and their pharmacokinetics and analgesic effect studied.
IT RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(sustained release pharmaceutical compds. to prevent abuse of controlled substances)
RN 849462-49-3 CAPLUS
CN L-Proline, α -L-glutamyl-5-oxo-, (5*u*)-6,7-didehydro-4,5-epoxy-3-methoxy-17-methylmorphinan-6-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L20 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:719446 CAPLUS
DOCUMENT NUMBER: 139:245813
TITLE: Preparation of 8-azaprostaglandin derivatives as EP2 and EP4 receptor agonists
INVENTOR(S): Tanil, Kousuke; Kobayashi, Kaoru; Maruyama, Toru; Kambe, Tohru; Ogawa, Hikio; Shiroya, Tsutomu
PATENT ASSIGNEE(S): Ono Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 436 pp.
CODEN: PIXX02
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003074483	A1	20030912	WO 2003-JP2478	20030304
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2477715	AA	20030912	CA 2003-2477715	20030304
AU 2003211574	A1	20030916	AU 2003-211574	20030304
EP 1481976	A1	20041201	EP 2003-743585	20030304
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 200308166	A	20050118	BR 2003-8166	20030304
US 2005124577	A1	20050609	US 2003-506536	20030304
CN 1653046	A	20050810	CN 2003-810251	20030304
NZ 535024	A	20061027	NZ 2003-535024	20030304
ZA 2004007034	A	20050309	ZA 2004-7034	20040902
NO 2004003702	A	20041203	NO 2004-3702	20040903
PRIORITY APPL. INFO.:				
			JP 2002-58487	A 20020305
			JP 2002-216567	A 20020725
			JP 2003-13447	A 20030122
			WO 2003-JP2478	W 20030304

OTHER SOURCE(S): MARPAT 139:245813
GI



L20 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 AB The title compds. I [T = O, etc.; X = CH₂, etc.; A = alkylene, etc.; D = CO₂H, etc.; E = UIU₂U₃, etc.; U₁ = alkylene, etc.; U₂ = CH₂, etc.; U₃ = (un)substituted alkyl, etc.] are prepared I are useful in preventing

and/or treating immune diseases, allergic diseases, nerve cell death, premature birth, misbirth, baldness, retinal neuropathy such as glaucoma, erectile dysfunction, arthritis, pulmonary injury, pulmonary fibrosis, pulmonary emphysema, bronchitis, chronic obstructive pulmonary disease, hepatic injury, acute hepatitis, cirrhosis, shock, nephritis, renal

insufficiency, circulatory diseases, systemic inflammatory response syndrome, sepsis, Still's disease, Kawasaki's disease, burn, systemic granuloma, ulcerative colitis, Crohn's disease, hypercytokinemia at dialysis, multiorgan failure, bone diseases, etc. In an in vitro test for binding to the EP2 receptor, one compound of this invention showed the K_i value of 14 nM. Formulations are given.

IT 597571-73-8P 597571-74-9P 597571-85-2P
 597572-15-1P 597572-16-2P 597572-33-3P
 597572-34-4P 597572-35-5P 597572-36-6P
 597572-37-7P 597572-38-8P 597572-39-9P
 597572-40-2P 597572-41-3P 597572-42-4P
 597572-43-5P 597572-44-6P 597572-45-7P
 597572-46-8P 597572-47-9P 597572-48-0P
 597572-49-1P 597572-50-4P 597572-51-5P
 597572-52-6P 597572-53-7P 597572-54-8P
 597572-55-9P 597572-56-0P 597572-57-1P
 597572-58-2P 597572-59-3P 597572-60-6P
 597572-61-7P 597572-62-8P 597572-63-9P
 597572-64-0P 597572-65-1P 597572-66-2P
 597572-67-3P 597572-68-4P 597572-69-5P
 597572-70-8P 597572-71-9P 597572-72-0P
 597572-73-1P 597572-74-2P 597572-75-3P
 597572-76-4P 597572-77-5P 597572-78-6P
 597572-79-7P 597572-91-3P 597572-92-4P
 597572-93-5P 597572-94-6P 597572-95-7P
 597572-96-8P 597572-97-9P 597572-98-0P
 597572-99-1P 597573-00-7P 597573-01-8P
 597573-05-2P 597573-08-5P 597573-09-6P
 597573-10-9P 597573-11-0P 597573-12-1P
 597573-13-2P 597573-14-3P 597573-23-4P
 597573-29-0P 597573-30-3P 597573-31-4P
 597573-32-5P 597573-36-9P 597573-38-1P
 597573-39-2P 597573-40-5P 597573-41-6P
 597573-42-7P 597573-43-8P 597573-44-9P
 597573-45-0P 597573-46-1P 597573-47-2P
 597573-48-3P 597573-50-7P 597573-51-8P
 597573-52-9P 597573-53-0P 597573-55-2P
 597573-56-3P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 8-azaprostaglandin derivs. as EP2 and EP4 receptor agonists)

RN 597571-73-8 CAPLUS
 CN 4-Thiazolecarboxylic acid, 2-[[2-[(5R)-2-oxo-5-(phenoxymethyl)-1-pyrrolidinyl]ethyl]thio]-, butyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L20 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 Absolute stereochemistry.




RN 597572-16-2 CAPLUS
 CN 4-Thiazolecarboxylic acid, 2-[[2-[(2R)-2-[(3,5-dichlorophenoxy)methyl]-5-oxo-1-pyrrolidinyl]ethyl]thio]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 597572-33-3 CAPLUS
 CN 4-Thiazolecarboxylic acid, 2-[[2-[(5R)-2-oxo-5-[(3-pyridinyloxy)methyl]-1-pyrrolidinyl]ethyl]thio]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 597572-34-4 CAPLUS
 CN 4-Thiazolecarboxylic acid, 2-[[2-[(2R)-2-[(2,5-dichlorophenoxy)methyl]-5-oxo-1-pyrrolidinyl]ethyl]thio]- (9CI) (CA INDEX NAME)

L20 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 597571-74-9 CAPLUS
 CN 4-Thiazolecarboxylic acid, 2-[[2-[(2R)-2-[(3,5-dichlorophenoxy)methyl]-5-oxo-1-pyrrolidinyl]ethyl]thio]-, butyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 597571-85-2 CAPLUS
 CN 4-Thiazolecarboxylic acid, 2-[[2-[(5R)-2-oxo-5-[(3-pyridinyloxy)methyl]-1-pyrrolidinyl]ethyl]thio]-, butyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 597572-15-1 CAPLUS
 CN 4-Thiazolecarboxylic acid, 2-[[2-[(5R)-2-oxo-5-(phenoxymethyl)-1-pyrrolidinyl]ethyl]thio]- (9CI) (CA INDEX NAME)


L20 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

Absolute stereochemistry.




RN 597572-35-5 CAPLUS
 CN 4-Thiazolecarboxylic acid, 2-[[2-[(5R)-2-oxo-5-[(2,4,5-trichlorophenoxy)methyl]-1-pyrrolidinyl]ethyl]thio]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 597572-36-6 CAPLUS
 CN 4-Thiazolecarboxylic acid, 2-[[2-[(2R)-2-[(3,4-dichlorophenoxy)methyl]-5-oxo-1-pyrrolidinyl]ethyl]thio]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 597572-37-7 CAPLUS
 CN 4-Thiazolecarboxylic acid, 2-[[2-[(5R)-2-oxo-5-


L20 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 [(pentafluorophenoxy)methyl]-1-pyrrolidinyl]ethyl]thio]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 597572-38-8 CAPLUS
 CN 4-Thiazolecarboxylic acid, 2-[[2-[(2R)-2-[(3,4-difluorophenoxy)methyl]-5-oxo-1-pyrrolidinyl]ethyl]thio]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 597572-39-9 CAPLUS
 CN 4-Thiazolecarboxylic acid, 2-[[2-[(2R)-2-[(3-methyl-2-nitrophenoxy)methyl]-5-oxo-1-pyrrolidinyl]ethyl]thio]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L20 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 597572-43-5 CAPLUS
 CN 4-Thiazolecarboxylic acid, 2-[[2-[(2R)-2-[(4-chloro-3-methylphenoxy)methyl]-5-oxo-1-pyrrolidinyl]ethyl]thio]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 597572-44-6 CAPLUS
 CN 4-Thiazolecarboxylic acid, 2-[[2-[(2R)-2-[(4-methyl-3-nitrophenoxy)methyl]-5-oxo-1-pyrrolidinyl]ethyl]thio]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 597572-45-7 CAPLUS
 CN 4-Thiazolecarboxylic acid, 2-[[2-[(2R)-2-[(3-bromophenoxy)methyl]-5-oxo-1-


L20 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 597572-40-2 CAPLUS
 CN 4-Thiazolecarboxylic acid, 2-[[2-[(2R)-2-[(3-chloro-4-formylphenoxy)methyl]-5-oxo-1-pyrrolidinyl]ethyl]thio]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 597572-41-3 CAPLUS
 CN 4-Thiazolecarboxylic acid, 2-[[2-[(2R)-2-[(3-methyl-4-nitrophenoxy)methyl]-5-oxo-1-pyrrolidinyl]ethyl]thio]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 597572-42-4 CAPLUS
 CN 4-Thiazolecarboxylic acid, 2-[[2-[(2R)-2-[(2-methyl-3-nitrophenoxy)methyl]-5-oxo-1-pyrrolidinyl]ethyl]thio]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L20 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 pyrrolidinyl]ethyl]thio]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 597572-46-8 CAPLUS
 CN 4-Thiazolecarboxylic acid, 2-[[2-[(2R)-2-[(2,3-dimethylphenoxy)methyl]-5-oxo-1-pyrrolidinyl]ethyl]thio]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 597572-47-9 CAPLUS
 CN 4-Thiazolecarboxylic acid, 2-[[2-[(2R)-2-[(4-chloro-2,6-dimethylphenoxy)methyl]-5-oxo-1-pyrrolidinyl]ethyl]thio]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L20 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 597572-48-0 CAPLUS
CN 4-Thiazolecarboxylic acid, 2-[[2-[(2R)-2-[(2-naphthalenyloxy)methyl]-5-oxo-1-pyrrolidinyl]ethyl]thio]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 597572-49-1 CAPLUS
CN 4-Thiazolecarboxylic acid, 2-[[2-[(2R)-2-[[2-fluoro-3-(trifluoromethyl)phenoxy]methyl]-5-oxo-1-pyrrolidinyl]ethyl]thio]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 597572-50-4 CAPLUS
CN 4-Thiazolecarboxylic acid, 2-[[2-[(2R)-2-[(3,5-dimethylphenoxy)methyl]-5-oxo-1-pyrrolidinyl]ethyl]thio]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L20 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


CN 4-Thiazolecarboxylic acid, 2-[[2-[(2R)-2-[(4-acetyl-3-methylphenoxy)methyl]-5-oxo-1-pyrrolidinyl]ethyl]thio]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 597572-54-8 CAPLUS
CN 4-Thiazolecarboxylic acid, 2-[[2-[(2R)-2-[(1-naphthalenyloxy)methyl]-5-oxo-1-pyrrolidinyl]ethyl]thio]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 597572-55-9 CAPLUS
CN 4-Thiazolecarboxylic acid, 2-[[2-[(2R)-2-[[2-chloro-3-(trifluoromethyl)phenoxy]methyl]-5-oxo-1-pyrrolidinyl]ethyl]thio]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L20 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 597572-51-5 CAPLUS
CN 4-Thiazolecarboxylic acid, 2-[[2-[(5R)-2-oxo-5-[[3,4,5-trimethylphenoxy]methyl]-1-pyrrolidinyl]ethyl]thio]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 597572-52-6 CAPLUS
CN 4-Thiazolecarboxylic acid, 2-[[2-[(5R)-2-oxo-5-[[5,6,7,8-tetrahydro-1-naphthalenyl]oxy]methyl]-1-pyrrolidinyl]ethyl]thio]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 597572-53-7 CAPLUS

L20 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 597572-56-0 CAPLUS
CN 4-Thiazolecarboxylic acid, 2-[[2-[(2R)-2-[(3-methylphenoxy)methyl]-5-oxo-1-pyrrolidinyl]ethyl]thio]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 597572-57-1 CAPLUS
CN 4-Thiazolecarboxylic acid, 2-[[2-[(2R)-2-[(4-methylphenoxy)methyl]-5-oxo-1-pyrrolidinyl]ethyl]thio]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 597572-58-2 CAPLUS
CN 4-Thiazolecarboxylic acid, 2-[[2-[(5R)-2-oxo-5-[[2,3,5-trichlorophenoxy]methyl]-1-pyrrolidinyl]ethyl]thio]- (9CI) (CA INDEX NAME)


L20 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)

Absolute stereochemistry.




RN 597572-59-3 CAPLUS
CN 4-Thiazolecarboxylic acid, 2-([2-((2R)-2-((3-chloro-4-fluorophenoxy)methyl)-5-oxo-1-pyrrolidinyl)ethyl]thio)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 597572-60-6 CAPLUS
CN 4-Thiazolecarboxylic acid, 2-([2-((2R)-2-((2,3-dichlorophenoxy)methyl)-5-oxo-1-pyrrolidinyl)ethyl]thio)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 597572-61-7 CAPLUS

L20 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)




RN 597572-64-0 CAPLUS
CN 4-Thiazolecarboxylic acid, 2-([2-((2R)-2-((2-chloro-4-methoxyphenoxy)methyl)-5-oxo-1-pyrrolidinyl)ethyl]thio)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 597572-65-1 CAPLUS
CN 4-Thiazolecarboxylic acid, 2-([2-((2R)-2-((4-chloro-3-methoxyphenoxy)methyl)-5-oxo-1-pyrrolidinyl)ethyl]thio)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 597572-66-2 CAPLUS
CN 4-Thiazolecarboxylic acid, 2-([2-((2R)-2-((2,3-dihydro-7-methyl-1H-inden-2-yloxy)methyl)-5-oxo-1-pyrrolidinyl)ethyl]thio)- (9CI) (CA INDEX NAME)

L20 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)


CN 4-Thiazolecarboxylic acid, 2-([2-((2R)-2-((3-nitrophenoxy)methyl)-5-oxo-1-pyrrolidinyl)ethyl]thio)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 597572-62-8 CAPLUS
CN 4-Thiazolecarboxylic acid, 2-([2-((5R)-2-oxo-5-[[3-(trifluoromethyl)phenoxy]methyl]-1-pyrrolidinyl)ethyl]thio)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 597572-63-9 CAPLUS
CN 4-Thiazolecarboxylic acid, 2-([2-((5R)-2-oxo-5-[[3-(trifluoromethoxy)phenoxy]methyl]-1-pyrrolidinyl)ethyl]thio)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L20 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)

Absolute stereochemistry.




RN 597572-67-3 CAPLUS
CN 4-Thiazolecarboxylic acid, 2-([2-((2R)-2-((4-fluoro-3-methylphenoxy)methyl)-5-oxo-1-pyrrolidinyl)ethyl]thio)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 597572-68-4 CAPLUS
CN 4-Thiazolecarboxylic acid, 2-([2-((5R)-2-oxo-5-[[2,3,4-trichlorophenoxy]methyl]-1-pyrrolidinyl)ethyl]thio)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 597572-69-5 CAPLUS
CN 4-Thiazolecarboxylic acid, 2-[[2-[(2R)-2-[[2-chloro-4-fluorophenoxy)methyl]-5-oxo-1-pyrrolidinyl]ethyl]thio]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 597572-70-8 CAPLUS
CN 4-Thiazolecarboxylic acid, 2-[[2-[(2R)-2-[[4-chloro-3-nitrophenoxy)methyl]-5-oxo-1-pyrrolidinyl]ethyl]thio]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 597572-71-9 CAPLUS
CN 4-Thiazolecarboxylic acid, 2-[[2-[(2R)-2-[[2,4-dichlorophenoxy)methyl]-5-oxo-1-pyrrolidinyl]ethyl]thio]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 597572-75-3 CAPLUS
CN 4-Thiazolecarboxylic acid, 2-[[2-[(2R)-2-[[3-methyl-4-(methylthio)phenoxy)methyl]-5-oxo-1-pyrrolidinyl]ethyl]thio]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 597572-76-4 CAPLUS
CN 4-Thiazolecarboxylic acid, 2-[[2-[(2R)-2-[[4-chloro-3,5-dimethylphenoxy)methyl]-5-oxo-1-pyrrolidinyl]ethyl]thio]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Absolute stereochemistry.




RN 597572-72-0 CAPLUS
CN 4-Thiazolecarboxylic acid, 2-[[2-[(2R)-2-[[4-chloro-3-(trifluoromethyl)phenoxy)methyl]-5-oxo-1-pyrrolidinyl]ethyl]thio]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 597572-73-1 CAPLUS
CN 4-Thiazolecarboxylic acid, 2-[[2-[(2R)-2-[[2,4-dimethylphenoxy)methyl]-5-oxo-1-pyrrolidinyl]ethyl]thio]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 597572-74-2 CAPLUS
CN 4-Thiazolecarboxylic acid, 2-[[2-[(2R)-2-[[3-ethylphenoxy)methyl]-5-oxo-1-pyrrolidinyl]ethyl]thio]- (9CI) (CA INDEX NAME)


RN 597572-77-5 CAPLUS
CN 4-Thiazolecarboxylic acid, 2-[[2-[(5R)-2-oxo-5-[[2,3,5-trifluorophenoxy)methyl]-1-pyrrolidinyl]ethyl]thio]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 597572-78-6 CAPLUS
CN 4-Thiazolecarboxylic acid, 2-[[2-[(2R)-2-[[4-fluoro-3-(trifluoromethyl)phenoxy)methyl]-5-oxo-1-pyrrolidinyl]ethyl]thio]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 597572-79-7 CAPLUS
CN 4-Thiazolecarboxylic acid, 2-[[2-[(2R)-2-[[4-chloro-3-fluorophenoxy)methyl]-5-oxo-1-pyrrolidinyl]ethyl]thio]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 597572-91-3 CAPLUS
CN 2-Pyrrolidinone,
5-[(3,5-dichlorophenoxy)methyl]-1-[2-[(4-(hydroxymethyl)-
2-thiazolyl)thio]ethyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 597572-92-4 CAPLUS
CN 2-Pyrrolidinone,
5-[(3,5-dichlorophenoxy)methyl]-1-[2-[(4-(methoxymethyl)-
2-thiazolyl)thio]ethyl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 597572-93-5 CAPLUS
CN 4-Thiazolecarboxamide,
2-[[2-[(2R)-2-[(3,5-dichlorophenoxy)methyl]-5-oxo-1-
pyrrolidinyl]ethyl]thio]-N-methylsulfonyl- (9CI) (CA INDEX NAME)


RN 597572-96-8 CAPLUS
CN 4-Thiazolecarboxamide,
2-[[2-[(2R)-2-[(3,5-dichlorophenoxy)methyl]-5-oxo-1-
pyrrolidinyl]ethyl]thio]-N-methylsulfonyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 597572-97-9 CAPLUS
CN 4-Thiazolecarboxylic acid, N-benzoyl-2-[[2-[(2R)-2-[(3,5-
dichlorophenoxy)methyl]-5-oxo-1-pyrrolidinyl]ethyl]thio]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 597572-98-0 CAPLUS
CN 4-Thiazolecarboxylic acid,
2-[[2-[(2R)-2-[(2-naphthalenyloxy)methyl]-5-oxo-1-
pyrrolidinyl]ethyl]thio]-, butyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


pyrrolidinyl]ethyl]thio]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 597572-94-6 CAPLUS
CN 4-Thiazolecarboxamide,
2-[[2-[(2R)-2-[(3,5-dichlorophenoxy)methyl]-5-oxo-1-
pyrrolidinyl]ethyl]thio]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 597572-95-7 CAPLUS
CN Piperazine, 1-[[2-[[2-[(2R)-2-[(3,5-dichlorophenoxy)methyl]-5-oxo-1-
pyrrolidinyl]ethyl]thio]-4-thiazolyl]carbonyl]-4-methyl-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 597572-99-1 CAPLUS
CN 4-Thiazolecarboxylic acid,
2-[[2-[(2R)-2-[(3-ethylphenoxy)methyl]-5-oxo-1-
pyrrolidinyl]ethyl]thio]-, butyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 597573-00-7 CAPLUS
CN 4-Thiazolecarboxylic acid, 2-[[2-[(5R)-2-oxo-5-[[3-
(trifluoromethyl)phenoxy]methyl]-1-pyrrolidinyl]ethyl]thio]-, butyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 597573-01-8 CAPLUS
CN 4-Thiazolecarboxylic acid, 2-[[2-[(5R)-2-oxo-5-[[3-
(trifluoromethoxy)phenoxy]methyl]-1-pyrrolidinyl]ethyl]thio]-, butyl ester (9CI) (CA INDEX NAME)


L20 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 597573-05-2 CAPLUS
CN 4-Thiazolecarboxylic acid, 2-[[2-[(5R)-2-oxo-5-[(2-pyridinyloxy)methyl]-1-pyrrolidinyl]ethyl]thio]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 597573-08-5 CAPLUS
CN 4-Thiazolecarboxylic acid, 2-[[2-[(5R)-2-oxo-5-[(5,6,7,8-tetrahydro-5-oxo-1-naphthalenyl)oxy)methyl]-1-pyrrolidinyl]ethyl]thio]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L20 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 597573-11-0 CAPLUS
CN 4-Thiazolecarboxylic acid, 2-[[2-[(2R)-2-[(4-acetyl-3-fluorophenoxy)methyl]-5-oxo-1-pyrrolidinyl]ethyl]thio]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 597573-12-1 CAPLUS
CN 4-Thiazolecarboxylic acid, 2-[[2-[(2R)-2-[(3-ethynylphenoxy)methyl]-5-oxo-1-pyrrolidinyl]ethyl]thio]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 597573-13-2 CAPLUS
CN 4-Thiazolecarboxylic acid, 2-[[2-[(2R)-2-[(4-formyl-3-methoxyphenoxy)methyl]-5-oxo-1-pyrrolidinyl]ethyl]thio]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L20 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 597573-09-6 CAPLUS
CN 4-Thiazolecarboxylic acid, 2-[[2-[(2R)-2-[(3,5-difluorophenoxy)methyl]-5-oxo-1-pyrrolidinyl]ethyl]thio]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 597573-10-9 CAPLUS
CN 4-Thiazolecarboxylic acid, 2-[[2-[(2R)-2-[(4-methoxy-2-nitrophenoxy)methyl]-5-oxo-1-pyrrolidinyl]ethyl]thio]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L20 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 597573-14-3 CAPLUS
CN 4-Thiazolecarboxylic acid, 2-[[2-[(2R)-2-[(2-chloro-3,5-difluorophenoxy)methyl]-5-oxo-1-pyrrolidinyl]ethyl]thio]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 597573-23-4 CAPLUS
CN 4-Thiazolecarboxylic acid, 2-[[2-[(2R)-2-[(3-(dimethylamino)phenoxy)methyl]-5-oxo-1-pyrrolidinyl]ethyl]thio]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 597573-29-0 CAPLUS
CN 4-Thiazolecarboxylic acid, 2-[[2-[(5R)-2-oxo-5-[(2-pyridinyloxy)methyl]-1-


L20 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
pyrrolidinyl]ethyl]thio]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 597573-30-3 CAPLUS
CN 4-Thiazolecarboxylic acid,
2-[[2-[(5R)-2-oxo-5-[(5-quinolinylloxy)methyl]-1-
pyrrolidinyl]ethyl]thio]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 597573-31-4 CAPLUS
CN 4-Thiazolecarboxylic acid,
2-[[2-[(5R)-2-oxo-5-[(6-quinolinylloxy)methyl]-1-
pyrrolidinyl]ethyl]thio]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L20 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN 4-Thiazolecarboxylic acid, 2-[[2-[(5R)-2-oxo-5-[[4-(trifluoromethoxy)phenoxy]methyl]-1-pyrrolidinyl]ethyl]thio]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 597573-39-2 CAPLUS
CN 4-Thiazolecarboxylic acid, 2-[[2-[(5R)-2-oxo-5-[[4-(trifluoromethoxy)phenoxy]methyl]-1-pyrrolidinyl]ethyl]thio]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 597573-40-5 CAPLUS
CN 4-Thiazolecarboxylic acid, 2-[[2-[(2R)-2-[(3-(1,1-dimethylethyl)phenoxy]methyl]-5-oxo-1-pyrrolidinyl]ethyl]thio]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L20 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 597573-32-5 CAPLUS
CN 4-Thiazolecarboxylic acid,
2-[[2-[(5R)-2-oxo-5-[(8-quinolinylloxy)methyl]-1-
pyrrolidinyl]ethyl]thio]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 597573-36-9 CAPLUS
CN 4-Thiazolecarboxylic acid,
2-[[2-[(5R)-2-oxo-5-[(4-pyridinylloxy)methyl]-1-
pyrrolidinyl]ethyl]thio]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 597573-38-1 CAPLUS

L20 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 597573-41-6 CAPLUS
CN 4-Thiazolecarboxylic acid,
2-[[2-[(2R)-2-[(4-chlorophenoxy)methyl]-5-oxo-1-
pyrrolidinyl]ethyl]thio]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 597573-42-7 CAPLUS
CN 4-Thiazolecarboxylic acid, 2-[[2-[(2R)-2-[(2-chloro-5-methylphenoxy)methyl]-5-oxo-1-pyrrolidinyl]ethyl]thio]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 597573-43-8 CAPLUS
CN 4-Thiazolecarboxylic acid, 2-[[2-[(2R)-2-[(3-chloro-5-methoxyphenoxy)methyl]-5-oxo-1-pyrrolidinyl]ethyl]thio]- (9CI) (CA INDEX NAME)


L20 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
NAME)

Absolute stereochemistry.




RN 597573-44-9 CAPLUS
CN 4-Thiazolecarboxylic acid, 2-[[2-[(2R)-2-[(2-acetyl-4-chloro-5-methylphenoxy)methyl]-5-oxo-1-pyrrolidinyl]ethyl]thio]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 597573-45-0 CAPLUS
CN 4-Thiazolecarboxylic acid, 2-[[2-[(2R)-2-[(3-methoxyphenoxy)methyl]-5-oxo-1-pyrrolidinyl]ethyl]thio]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L20 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 597573-50-7 CAPLUS
CN 4-Thiazolecarboxylic acid, 2-[[2-[(2R)-2-[(3-aminophenoxy)methyl]-5-oxo-1-pyrrolidinyl]ethyl]thio]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 597573-51-8 CAPLUS
CN 4-Thiazolecarboxylic acid, 2-[[2-[(2R)-2-[(3-(methylamino)phenoxy)methyl]-5-oxo-1-pyrrolidinyl]ethyl]thio]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 597573-52-9 CAPLUS
CN 4-Thiazolecarboxylic acid, 2-[[2-[(2R)-2-[(3-amino-2-methylphenoxy)methyl]-5-oxo-1-pyrrolidinyl]ethyl]thio]- (9CI) (CA INDEX NAME)


L20 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 597573-46-1 CAPLUS
CN 4-Thiazolecarboxylic acid, 2-[[2-[(2R)-2-[(3-ethoxyphenoxy)methyl]-5-oxo-1-pyrrolidinyl]ethyl]thio]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 597573-47-2 CAPLUS
CN 4-Thiazolecarboxylic acid, 2-[[2-[(2R)-2-[(3-(difluoromethoxy)phenoxy)methyl]-5-oxo-1-pyrrolidinyl]ethyl]thio]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 597573-48-3 CAPLUS
CN 4-Thiazolecarboxylic acid, 2-[[2-[(5R)-2-oxo-5-[[3-(1,1,2,2-tetrafluoroethoxy)phenoxy)methyl]-1-pyrrolidinyl]ethyl]thio]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L20 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
5-oxo-1-pyrrolidinyl]ethyl]thio]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 597573-53-0 CAPLUS
CN 4-Thiazolecarboxylic acid, 2-[[2-[(2R)-2-[(3-amino-4-methylphenoxy)methyl]-5-oxo-1-pyrrolidinyl]ethyl]thio]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 597573-55-2 CAPLUS
CN 4-Thiazolecarboxylic acid, 2-[[2-[(2R)-2-[(3-(aminomethyl)phenoxy)methyl]-5-oxo-1-pyrrolidinyl]ethyl]thio]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L20 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)
RN 597573-56-3 CAPLUS
CN 4-Thiazolecarboxylic acid,
2-[[2-[(2R)-2-[[3-[(dimethylamino)methyl]phenox
y)methyl]-5-oxo-1-pyrrolidinyl]ethyl]thio]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR
THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L20 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 1993:539078 CAPLUS
DOCUMENT NUMBER: 119:139078
TITLE: Preparation of 5-[(aminoaryloxy)methyl]-2-pyrrolidinoneacetates and analogs as drugs
Himmelsbach, Frank; Austel, Volkhart; Pieper, Helmut; Eisert, Wolfgang; Mueller, Thomas; Weisenberger, Johannes; Linz, Guenter; Krueger, Gerd
Thomae, Dr. Karl, G.m.b.H., Germany
Eur. Pat. Appl., 173 pp.
CODEN: EPKXDW
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 483667	A2	19920506	EP 1991-118148	19911024
EP 483667	A3	19920916		
EP 483667	B1	19980204		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
DE 4035961	A1	19920507	DE 1990-4035961	19901102
AT 163008	E	19980215	AT 1991-118148	19911024
ES 2113867	T3	19980516	ES 1991-118148	19911024
SG 81852	A1	20010724	SG 1996-1241	19911024
FI 9105136	A	19920503	FI 1991-5136	19911031
FI 107606	B1	20010914		
CA 2054850	AA	19920503	CA 1991-2054850	19911101
CA 2054850	C	20010102		
NO 9104294	A	19920504	NO 1991-4294	19911101
NO 174806	B	19940405		
NO 174806	C	19940713		
AU 9186926	A1	19920507	AU 1991-86926	19911101
AU 650488	B2	19940623		
JP 04264068	A2	19920918	JP 1991-313154	19911101
JP 2937589	B2	19990823		
HU 67288	A2	19950328	HU 1991-3455	19911101
RU 2040519	C1	19950725	RU 1991-5001905	19911101
IL 95926	A1	19960618	IL 1991-95926	19911101
KR 223135	B1	19991015	KR 1991-19458	19911102
ZA 9108734	A	19930504	ZA 1991-8734	19911104
US 5541343	A	19960730	US 1994-365336	19941228
US 5591769	A	19970107	US 1995-458096	19950601
PRIORITY APPLN. INFO.:			DE 1990-4035961	A 19901102
			US 1991-783065	B1 19911025
			US 1994-365336	A3 19941228

OTHER SOURCE(S): MARPAT 119:139078
GI


L20 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



AB Comps. BXAYE [A = 4- to 7-membered (substituted) alkyleneiminodiyl; B = cyano, NO2, NH2, C(:NH)NH2, NHC(:NH)NH2, etc.; E = vinyl, CH2OH, cyano, SO2H, CO2H, alkoxy, carbonyl, etc.; X = X5X4X3X2X1; X1 = bond, alkylene, or arylene which may be linked to X2 by O, SO2, CO, etc.; X2 = fluorenylene, arylene, hydronaphthalenylylene, etc.; X3, X5 = bond, (unsatd.) alkylene, etc.; X4 = bond, arylene, (bi)cycloalkylene; Y = Y1Y2Y3; Y1, Y2 = bond, (unsatd.) alkylene, etc.; Y3 = bond, arylene, alkylenearylene, etc.] were prepared. Thus, (S)-5-[(trityloxy)methyl]-2-pyrrolidinone was condensed with Ph(CH2)3Br and the product alkylated with BrCH2CH:CH2 to give, after deprotection and mesylation, pyrrolidinone (3R,5S)-I (II; R1 = CH2CH:CH2, R2 = SO2Me) which was condensed with 4'-cyano-4-hydroxybiphenyl to give, after oxidation and esterification, II (R1 = CH2CO2Me, R2 = 4'-cyano-4-biphenyl). The latter was converted in 2 steps to title compound (3R,5S)-III (IV; n = 3). IV (n = 0) had IC50 of 0.024 μ M against binding of fibrinogen to human thrombocytes in vitro.

IT 149507-15-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, in preparation of drugs)
RN 149507-15-3 CAPLUS
CN 3-Pyrrolidinoneacetic acid,
5-[[[4'-cyano[1,1'-biphenyl]-4-yl]oxy]methyl]-1-(2-methoxyethyl)-2-oxo-, (3S-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 148377-20-2P 148377-21-3P 148377-22-4P
148377-23-5P 148377-32-6P 148377-33-7P
148377-72-4P 148377-73-5P 148377-74-6P

L20 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)

148395-19-1P 148395-20-4P 148395-40-8P
148396-24-1P 148396-25-2P 148396-30-9P
148396-79-6P 148396-80-9P 148396-89-8P
149501-06-4P 149501-07-5P 149501-72-4P
149503-23-1P 149503-24-2P 149503-25-3P
149503-26-4P 149503-53-7P 149503-54-8P
149503-55-9P 149503-56-0P 149503-57-1P
149504-02-9P 149504-03-0P 149504-04-1P
149504-05-2P
RL: BAC (Biological activity or effector, except adverse): BSU
(Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of, as drug)
RN 148377-20-2 CAPLUS
CN 1,3-Pyrrolidinediacetic acid,
5-[[[4'-((aminoiminomethyl)[1,1'-biphenyl]-4-yl]oxy)methyl]-2-oxo-, dimethyl ester, monohydrochloride, (3S-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 148377-21-3 CAPLUS
CN 3-Pyrrolidinediacetic acid, 5-[[[4'-((aminoiminomethyl)[1,1'-biphenyl]-4-yl]oxy)methyl]-1-(2-(ethylamino)-2-oxoethyl)-2-oxo-, methyl ester, monohydrochloride, (3S-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 148377-22-4 CAPLUS
 CN 3-Pyrrolidineacetic acid, 5-[[[4'-(aminoiminomethyl)[1,1'-biphenyl]-4-yl]oxy]methyl]-1-[2-(dimethylamino)-2-oxoethyl]-2-oxo-, methyl ester, monohydrochloride, (3S-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 148377-23-5 CAPLUS
 CN 3-Pyrrolidineacetic acid, 5-[[[4'-(aminoiminomethyl)[1,1'-biphenyl]-4-yl]oxy]methyl]-1-[2-oxo-2-[(phenylmethyl)amino]ethyl]-, methyl ester, monohydrochloride, (3S-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 148377-72-4 CAPLUS
 CN 3-Pyrrolidineacetic acid, 5-[[[4'-(aminoiminomethyl)[1,1'-biphenyl]-4-yl]oxy]methyl]-1-[2-(ethylamino)-2-oxoethyl]-2-oxo-, monohydrochloride, (3S-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 148377-73-5 CAPLUS
 CN 3-Pyrrolidineacetic acid, 5-[[[4'-(aminoiminomethyl)[1,1'-biphenyl]-4-yl]oxy]methyl]-1-[2-(dimethylamino)-2-oxoethyl]-2-oxo-, monohydrochloride, (3S-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 148377-32-6 CAPLUS
 CN 3-Pyrrolidineacetic acid, 5-[[[4'-(aminoiminomethyl)[1,1'-biphenyl]-4-yl]oxy]methyl]-1-[2-methoxyethyl]-2-oxo-, methyl ester, monohydrochloride, (3S-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 148377-33-7 CAPLUS
 CN 3-Pyrrolidineacetic acid, 5-[[[4'-(aminoiminomethyl)[1,1'-biphenyl]-4-yl]oxy]methyl]-1-[2-hydroxyethyl]-2-oxo-, methyl ester, monohydrochloride, (3S-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 148377-74-6 CAPLUS
 CN 3-Pyrrolidineacetic acid, 5-[[[4'-(aminoiminomethyl)[1,1'-biphenyl]-4-yl]oxy]methyl]-1-[2-amino-2-oxoethyl]-2-oxo-, monohydrochloride, (3S-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 148395-19-1 CAPLUS
 CN 1-Pyrrolidineacetamide, 5-[[[4'-cyano[1,1'-biphenyl]-4-yl]oxy]methyl]-2-oxo-3-(2-propenyl)-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L20 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 148395-20-4 CAPLUS
CN 1-Pyrrolidineacetic acid, 5-[[[4'-cyano[1,1'-biphenyl]-4-yl]oxy]methyl]-2-oxo-3-(2-propenyl)-, methyl ester, (3R-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 148395-40-8 CAPLUS
CN [1,1'-Biphenyl]-4-carbonitrile, 4'-[[5-oxo-1-[2-(phenylmethoxy)ethyl]-4-(2-propenyl)-2-pyrrolidinyl]methoxy]-, (2S-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L20 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 148396-79-6 CAPLUS
CN 1,3-Pyrrolidinediacetic acid, 5-[[[4'-(aminoiminomethyl)[1,1'-biphenyl]-4-yl]oxy]methyl]-2-oxo-, (3S-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 148396-80-9 CAPLUS
CN 3-Pyrrolidineacetic acid, 5-[[[4'-(aminoiminomethyl)[1,1'-biphenyl]-4-yl]oxy]methyl]-2-oxo-1-[2-oxo-2-[[phenylmethyl]amino]ethyl]-, (3S-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L20 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 148396-24-1 CAPLUS
CN 3-Pyrrolidineacetic acid, 5-[[[4'-cyano[1,1'-biphenyl]-4-yl]oxy]methyl]-1-(2-methoxyethyl)-2-oxo-, methyl ester, (3S-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 148396-25-2 CAPLUS
CN 3-Pyrrolidineacetic acid, 1-[2-(acetyloxy)ethyl]-5-[[[4'-cyano[1,1'-biphenyl]-4-yl]oxy]methyl]-2-oxo-, methyl ester, (3S-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 148396-30-9 CAPLUS
CN 3-Pyrrolidineacetic acid, 5-[[[4'-(aminoiminomethyl)[1,1'-biphenyl]-4-yl]oxy]methyl]-1-(2-hydroxyethyl)-2-oxo-, (3S-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L20 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 148396-89-8 CAPLUS
CN 3-Pyrrolidineacetic acid, 5-[[[4'-(aminoiminomethyl)[1,1'-biphenyl]-4-yl]oxy]methyl]-1-(2-methoxyethyl)-2-oxo-, (3S-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 149501-06-4 CAPLUS
CN 1-Pyrrolidineacetamide, 5-[[[4'-cyano[1,1'-biphenyl]-4-yl]oxy]methyl]-N-ethyl-2-oxo-3-(2-propenyl)-, (2S-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 149501-07-5 CAPLUS
CN 1-Pyrrolidineacetamide, 5-[[[4'-cyano[1,1'-biphenyl]-4-yl]oxy]methyl]-N,N-dimethyl-2-oxo-3-(2-propenyl)-, (2S-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 149501-72-4 CAPLUS
CN 1-Pyrrolidineacetic acid,
5-[[[4'-cyano[1,1'-biphenyl]-4-yl]oxy]methyl]-2-
oxo-3-(2-propenyl)-, (3R-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 149503-23-1 CAPLUS
CN 1,3-Pyrrolidinediacetic acid, 5-[[[4'-cyano[1,1'-biphenyl]-4-yl]oxy]methyl]-2-oxo-, dimethyl ester, (3S-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 149503-24-2 CAPLUS
CN 3-Pyrrolidineacetic acid,
5-[[[4'-cyano[1,1'-biphenyl]-4-yl]oxy]methyl]-1-
2-oxo-1-[2-(ethylamino)-2-oxoethyl]-2-oxo-, methyl ester, (3S-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 149503-25-3 CAPLUS
CN 3-Pyrrolidineacetic acid,
5-[[[4'-cyano[1,1'-biphenyl]-4-yl]oxy]methyl]-1-
2-oxo-1-[2-(dimethylamino)-2-oxoethyl]-2-oxo-, methyl ester, (3S-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 149503-26-4 CAPLUS
CN 3-Pyrrolidineacetic acid,
5-[[[4'-cyano[1,1'-biphenyl]-4-yl]oxy]methyl]-2-
oxo-1-[2-oxo-2-(phenylmethylamino)ethyl]-, methyl ester, (3S-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 149503-53-7 CAPLUS
CN 1-Pyrrolidineacetamide, 5-[[[4'-cyano[1,1'-biphenyl]-4-yl]oxy]methyl]-2-
oxo-N-(phenylmethyl)-3-(2-propenyl)-, (2S-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 149503-54-8 CAPLUS
CN 3-Pyrrolidineacetic acid, 5-[[[4'-aminoiminomethyl][1,1'-biphenyl]-4-yl]oxy]methyl]-1-(2-amino-2-oxoethyl)-2-oxo-, methyl ester, hydrochloride (5:1), (3S-trans)- (9CI) (CA INDEX NAME)




● 1/5 HCl

RN 149503-55-9 CAPLUS
CN [1,1'-Biphenyl]-4-carbonitrile, 4'-[[[1-(2-methoxyethyl)-5-oxo-4-(2-


propenyl]-2-pyrrolidinyl]methoxy]-, (2S-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 149503-56-0 CAPLUS
CN [1,1'-Biphenyl]-4-carbonitrile, 4'-[[[1-(2-hydroxyethyl)-5-oxo-4-(2-propenyl)-2-pyrrolidinyl]methoxy]-, (2S-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 149503-57-1 CAPLUS
CN [1,1'-Biphenyl]-4-carbonitrile, 4'-[[[1-(2-(acetyloxy)ethyl)-5-oxo-4-(2-propenyl)-2-pyrrolidinyl]methoxy]-, (2S-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 149504-02-9 CAPLUS
CN 3-Pyrrolidineacetic acid, 1-(2-amino-2-oxoethyl)-5-[[[4'-cyano[1,1'-biphenyl]-4-yl]oxy]methyl]-2-oxo-, (3S-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 149504-03-0 CAPLUS
CN 3-Pyrrolidineacetic acid,
5-[[[4'-cyano[1,1'-biphenyl]-4-yl]oxy]methyl]-1-
[2-(ethylamino)-2-oxoethyl]-2-oxo-, (3S-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 149504-04-1 CAPLUS
CN 3-Pyrrolidineacetic acid,
5-[[[4'-cyano[1,1'-biphenyl]-4-yl]oxy]methyl]-1-
[2-(dimethylamino)-2-oxoethyl]-2-oxo-, (3S-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 149504-05-2 CAPLUS
CN 3-Pyrrolidineacetic acid,
5-[[[4'-cyano[1,1'-biphenyl]-4-yl]oxy]methyl]-2-
oxo-1-[2-oxo-2-[(phenylmethyl)amino]ethyl]-, (3S-trans)- (9CI) (CA INDEX NAME)


ACCESSION NUMBER: 1974:145704 CAPLUS
DOCUMENT NUMBER: 80:145704
TITLE: Reactions of substituted γ -valerolactams
AUTHOR(S): Arsenyan, G. B.; Arakelyan, S. V.; Danyan, M. T.
CORPORATE SOURCE: Erevan. Gos. Univ., Erevan, USSR
SOURCE: Armyanskii Khimicheskii Zhurnal (1973), 26(11), 939-43
CODEN: AYKZAN; ISSN: 0515-9628
DOCUMENT TYPE: Journal
LANGUAGE: Russian
GI For diagram(s), see printed CA Issue.
AB Chlorination of I (R = OH, R1 = Et, Bu) gave 54.6-55% I (R = Cl). Reaction of I (R = Cl, R1 = Bu) with 2-naphthol and EtONa gave 48.7% I (R = 2-naphthoxy, R1 = Bu). I (R = PhO, R1 = heptyl) was similarly prepared
Hydrolysis of II (R2 = 2-naphthyl) and I (R = OH, R1 = decyl) gave 63.2 and 63.9% of the corresponding acids, resp. Hydrazinolysis of III (R3 = phthalimido) gave 88.1% III (R3 = NH2) and hydrazinolysis of I (R = phthalimido, R1 = Me2CHCH, Bu) gave 94.4 and 72.8% of the corresponding I (R = NH2).

IT 52060-11-4 52060-13-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(diazotization of)

RN 52060-11-4 CAPLUS
CN 2-Pyrrolidinone, 1-(2-aminoethyl)-3-butyl-5-[(3-methylphenoxy)methyl]- (9CI) (CA INDEX NAME)





RN 52060-13-6 CAPLUS
CN 2-Pyrrolidinone, 1-(2-aminoethyl)-3-pentyl-5-(phenoxymethyl)- (9CI) (CA INDEX NAME)




IT 52060-15-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(hydrolysis of)

RN 52060-15-8 CAPLUS
CN 2-Pyrrolidinone, 1-(2-aminoethyl)-3-butyl-5-[(2-naphthalenyloxy)methyl]- (9CI) (CA INDEX NAME)



IT 52060-12-5P 52060-14-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 52060-12-5 CAPLUS
CN 2-Pyrrolidinone, 3-butyl-1-(2-hydroxyethyl)-5-[(3-methylphenoxy)methyl]- (9CI) (CA INDEX NAME)



RN 52060-14-7 CAPLUS
CN 2-Pyrrolidinone, 1-(2-hydroxyethyl)-3-pentyl-5-(phenoxymethyl)- (9CI) (CA INDEX NAME)

